| abstract |
The present invention relates to novel compounds of formula (II) and to compounds of formula (III) and pharmaceutically acceptable salts, esters, enantiomers, diastereomers, N-oxides, amides thereof. In the formulas, the substituents have the following meanings: R is C1-C15 alkyl, alkene, alkyne (straight or branched), aryl, substituted aryl or alkylaryl, R 'is SO2C6H5, SO2C6H4CH3-p, or SO2C6H4Cl-p, phenyl or substituent. Thus, C6H4-R '' '- p - wherein R' '' is C1, NO2, OCH3, CH3, CH2COOH, CH2COOCH3, CH2COLDVP, CH2CODVP, CH2COVP, where LDVP, DVP and VP are tetrapeptide (Leucyl-aspartyl-valyl-prolyl), tripeptide (aspartyl valyl prolyl) and dipeptide (valylprolyl), R <is H or CH 3 and R '<is epiglucofuranose, epiallofuranose, xylofuranose or ribofuranose configuration. The invention also relates to pharmaceutical compositions containing the above compounds and their use for inhibiting cell adhesion. HE |